FORCE’s eXamining the Relevance of Articles for Young Survivors (XRAYS) program is a reliable resource for breast cancer research-related news and information. XRAYS reviews new breast cancer research, provides plain-language summaries, and rates how the media covered the topic. XRAYS is funded by the CDC.
In this follow-up, we update a recent XRAYS on expanded genetic testing in Jewish women with breast cancer. An expert in the field suggests a different interpretation of the original study than the authors. We examine the key differences in interpretation of the data. (6/7/18)
Healthcare providers are bound by the guiding principle of doing no harm. But how does this concept apply to their patients who have not consented to genetic testing or who do not want to know their results? In that case, is providing test results more harmful or not? Anna Clausen explores these issues in the context of breast cancer gene testing in her Global Health Now article “The Right Not to Know: When Ignorance is Bliss but Deadly.” (4/20/18)
Interest in personalized genetic testing is growing. Genetic testing about health conditions typically requires a prescription from a health care provider. Until recently, the direct-to-consumer (DTC) testing market has focused on ancestry and discovery of unknown branches of family trees. A laboratory called 23andMe that provides direct-to-consumer genetic testing has been given FDA approval to report results for 3 mutations found in the BRCA1 and BRCA2 genes. The
FDA statement provides details about this approval and cautions consumers about the limitations of the 23andMe test. (03/19/18)
The link between alcohol intake and breast cancer is well known, but most studies have involved only White women. Recently, a large study of more than 22,000 African American (AA) women found that similar to White women, increased alcohol consumption is associated with a greater risk of breast cancer. (10/27/17)
Past studies using mostly animal models showed a link between use of hair products (dyes, straighteners and relaxers) and increased risk of certain cancers. In this study, researchers looked at data on hair product use among African-American (AA) and White women to see if certain types of hair products increased breast cancer risk, and how that risk might differ between race and breast cancer hormone status. (9/27/2017)
The majority of racial groups in the United States have seen declines in breast cancer rates. However, this study provides new insights into the patterns of breast cancer rates in Asian American subgroups in California. Using 26 years of data, this research found that breast cancer is rapidly increasing among this population, contrasting to a decline in rates among non-Hispanic white women in California and nationwide. (8/15/17)
Current tools used to calculate breast cancer risk make their estimations based on data from non-Hispanic white women and may not accurately predict breast cancer risk in women of other races and ethnicities. With further testing, a new risk assessment tool developed specifically for Hispanic women could more accurately predict breast cancer risk in women who do not have mutations in BRCA or other genes associated with hereditary breast cancer. (02/07/17)
"Hispanic" is a broad ethnic category that includes people from numerous countries. When discussing breast cancer statistics, Mexicans, Cubans, Puerto Ricans and people whose families originated in Central and South America are typically grouped into one Hispanic category. A new study looked at whether the country of origin affected breast cancer prevalence and mortality rates in Hispanic women in the U.S. (10/25/16)
Black women receive BRCA testing less frequently than white women. Why is that? Researchers thought the reason might be that black and white women see different health care providers. However, new research suggests that disparities in physician recommendations for testing are the cause: black women with breast cancer were less likely to receive physician recommendations for BRCA testing than white women with breast cancer. There is a need to ensure equity in physician testing recommendations for black women. (7/21/16)
Most estimates of the percentage of breast cancer patients with mutations in BRCA are based on studies of non-Hispanic white women. Researchers have found that the prevalence of BRCA mutations in black women diagnosed at a young age with breast cancer is approximately double that of previously reported estimates in non-Hispanic white women with breast cancer diagnosed in similar age categories. This study underscores the need for health care providers to refer for genetic counseling and testing all black women diagnosed with invasive breast cancer at or before age 50.
Diagnoses of ductal carcinoma in situ (DCIS), sometimes called stage 0 breast cancer, have increased in recent decades. Many people with DCIS wonder if they need aggressive treatment. A recent study looking at the survival of over 100,000 women found that breast cancer mortality after DCIS is low (3%), and identified groups of women who are at higher risk after DCIS.